STOCKS AND DRUGS, DRUGS AND STOCKS

Even this crow would not buy FFF*

But I might

Man, Wall Street and the Pharma industry are joined at the hip!  ASCO (American Society of Clinical Oncologists) is holding its annual meeting, and stock-advice companies (Seeking Alpha, The Motley Fool, etc.) are scouring the abstracts for tips.  If, for instance, Fumblefingers Fharma announces that its latest gazillion-dollar drug is doing well in a stage 2 trial, some outfit is sure to suggest that you jump into its stock with both feet.  Fumbelfingers stock (symbol FFF*) may jump as a result – but is damned likely to collapse once phase 3 trials reveal that it has unfortunate side effects: hair loss, tooth blackening and inverted eyeballs, for instance.  Take my advice, based on cruel experience – don’t buy FFF unless you have money to burn.

That leaves most of us out.

Here, for example:

  http://www.businessinsider.com/r-immunogen-drug-moving-ahead-in-single-agent-combination-trials-2017-5?r=UK&IR=T

*  I made FFF up, of course.